In November 2013 Janssen took part in the Belgian economic mission to India. The purpose of the trading mission was to strengthen and diversify economic relations between Belgium and India. Both Janssen and parent company Johnson & Johnson have had a long-standing and significant presence in India. 

Former Chairman of the Board of Directors of Janssen Pharmaceutica Ajit Shetty talked with the Indian Minister of Economic Affairs about the need for innovative and basic medicines. Out of a population of over 1,000 million people there are only 100 million Indians living prosperously. Although, happily, this group is continuing to grow, the figures clearly show that the need for essential medicines remains great. 

Janssen has already been investing in India for years. In 2007 the ‘Analytical and Pharmaceutical Development Center’ in Mumbai was extended and renovated. The center is now a hub for analytical and pharmaceutical development processes.

Both Janssen and parent company Johnson & Johnson have had a long-standing and significant presence in India. 

116246336.jpg

Durabilité
Économique

Janssen believes that strong corporate results, correct policies and focused activities pave the way towards economic sustainability. 

Janssen must constantly reinvent itself in order to cope with the structural and economic changes that affect its environment. This is why Janssen is committed to build partnerships within an open innovation model, and to the continuous alignment of its cost-competitiveness by only developing medicines with a high therapeutic added value. 

For Janssen this means specifically: being focused and a leader in research & development, and being efficient and progressive in terms of production with the aim of bringing new therapeutic solutions to patients quicker and at less expense, and implementing a growth strategy to ensure our continued investment in all these areas.